Cargando…

Author Correction: Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index

Detalles Bibliográficos
Autores principales:	Lee, Janghee, Cha, Chihwan, Ahn, Sung Gwe, Kim, Dooreh, Park, Soeun, Bae, Soong June, Kim, Jeeye, Park, Hyung Seok, Park, Seho, Kim, Seung Il, Park, Byeong‑Woo, Jeong, Joon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7940402/ https://www.ncbi.nlm.nih.gov/pubmed/33686136 http://dx.doi.org/10.1038/s41598-021-84773-x

Ejemplares similares

Validation of Clinical Treatment Score post-5 years (CTS5) risk stratification in premenopausal breast cancer patients and Ki-67 labelling index
por: Lee, Janghee, et al.
Publicado: (2020)

Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node‐positive, HER2‐positive breast cancer
por: Cha, Chihwan, et al.
Publicado: (2021)

Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy
por: Bae, Soong June, et al.
Publicado: (2020)

Relationship of the standard uptake value of (18)F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm
por: Park, Soeun, et al.
Publicado: (2021)

Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Early Standardized Uptake Value Reduction in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
por: Bae, Soong June, et al.
Publicado: (2022)

Ki-67 and breast cancer prognosis: does it matter if Ki-67 level is examined using preoperative biopsy or postoperative specimen?
por: Choi, Soon Bo, et al.
Publicado: (2022)

Comparison of complications according to incision types in nipple-sparing mastectomy and immediate reconstruction
por: Park, Soeun, et al.
Publicado: (2020)

Radiotherapy-Induced High Neutrophil-to-Lymphocyte Ratio is a Negative Prognostic Factor in Patients with Breast Cancer
por: Yoon, Chang Ik, et al.
Publicado: (2020)

The Impact of Post-Mastectomy Radiotherapy on Survival Outcomes in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy
por: Lee, Janghee, et al.
Publicado: (2021)

Characteristics and Survival of Breast Cancer Patients with Multiple Synchronous or Metachronous Primary Cancers
por: Lee, Janghee, et al.
Publicado: (2015)

Repeat Sentinel Lymph Node Biopsy for Ipsilateral Breast Tumor Recurrence After Breast Conserving Surgery With Sentinel Lymph Node Biopsy: Pooled Analysis Using Data From a Systematic Review and Two Institutions
por: Yoon, Chang Ik, et al.
Publicado: (2020)

Risk Factors Associated with Discordant Ki-67 Levels between Preoperative Biopsy and Postoperative Surgical Specimens in Breast Cancers
por: Kim, Hyung Sun, et al.
Publicado: (2016)

Ki-67, 21-Gene Recurrence Score, Endocrine Resistance, and Survival in Patients With Breast Cancer
por: Lee, Janghee, et al.
Publicado: (2023)

Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk
por: Bae, Soong June, et al.
Publicado: (2021)

Associations between absolute neutrophil count and lymphocyte-predominant breast cancer
por: Yoon, Chang Ik, et al.
Publicado: (2019)

Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Author Correction: Primary endocrine resistance of ER+ breast cancer with ESR1 mutations interrogated by droplet digital PCR
por: Ahn, Sung Gwe, et al.
Publicado: (2022)

Body mass index and absolute lymphocyte count predict disease-free survival in Korean breast cancer patients
por: Ko, Sung Min, et al.
Publicado: (2021)

Molecular subtyping of ependymoma and prognostic impact of Ki-67
por: Lim, Ka Young, et al.
Publicado: (2021)

Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis
por: Cha, Yoon Jin, et al.
Publicado: (2022)

Expression of Cyclooxygenase-2, p53 and Ki-67 in Gastric Cancer
por: Joo, Young-Eun, et al.
Publicado: (2006)

Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone.
por: Park, H. R., et al.
Publicado: (1995)

High Nuclear Expression of Yes-Associated Protein 1 Correlates With Metastasis in Patients With Breast Cancer
por: Cha, Yoon Jin, et al.
Publicado: (2021)

PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
por: Cha, Yoon Jin, et al.
Publicado: (2021)

Ki-67 as a Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Kim, Kwan Il, et al.
Publicado: (2014)

The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients
por: Cha, Yoon Jin, et al.
Publicado: (2021)

IHC-based Ki67 as response biomarker to tamoxifen in breast cancer window trials enrolling premenopausal women
por: Joosten, Stacey E. P., et al.
Publicado: (2021)

Prognostic impact of radiotherapy-induced-lymphopenia in patients treated with breast-conservative surgery
por: Yoon, Chang Ik, et al.
Publicado: (2023)

Metastasis Risk Assessment Using BAG2 Expression by Cancer-Associated Fibroblast and Tumor Cells in Patients with Breast Cancer
por: Yoon, Chang-Ik, et al.
Publicado: (2021)

(18)F-FDG uptake of visceral adipose tissue on preoperative PET/CT as a predictive marker for breast cancer recurrence
por: Kim, Hyun Jeong, et al.
Publicado: (2022)

Interobserver Variability of Ki-67 Measurement in Breast Cancer
por: Chung, Yul Ri, et al.
Publicado: (2016)

Prognostic Value of Immunohistochemical Staining of p53, bcl-2, and Ki-67 in Small Cell Lung Cancer
por: Paik, Kwang Hyun, et al.
Publicado: (2006)

Prognostic relevance of the Ki-67 proliferation index in patients with mantle cell lymphoma
por: Jeong, Tae-Dong, et al.
Publicado: (2016)

P16/Ki-67 Immunostaining is Useful in Stratification of Atypical Metaplastic Epithelium of the Cervix
por: Walts, Ann E., et al.
Publicado: (2008)

Ki-67 labeling index as a prognostic marker in advanced stomach cancer
por: Seo, Sang Hyuk, et al.
Publicado: (2019)

Low PR in ER(+)/HER2(−) breast cancer: high rates of TP53 mutation and high SUV
por: Ahn, Sung Gwe, et al.
Publicado: (2018)

Proliferation Marker Ki67 as a Stratification Index of Adjuvant Chemotherapy for Resectable Mucosal Melanoma
por: Tang, Lirui, et al.
Publicado: (2022)

Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer
por: Kim, Hohyun, et al.
Publicado: (2015)

The impact of pathologic differentiation (well/poorly) and the degree of Ki-67 index in patients with metastatic WHO grade 3 GEP-NECs
por: Kim, Hee Kyung, et al.
Publicado: (2017)

High A20 expression negatively impacts survival in patients with breast cancer
por: Yoon, Chang Ik, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_t4qdqkekjkkmu44btbvea06pnj